Document:

Amended and Restated Employment Agreement - Douglas A. Schuling

 Exhibit 10.15 
 AMENDED AND RESTATED 
 EXECUTIVE EMPLOYMENT AGREEMENT 
 THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT
AGREEMENT (“Agreement”) is made and entered into this 25th day of November, 2008 (the “Effective Date”) by and between GENOPTIX,
INC., a Delaware corporation (“Company”), and DOUGLAS A. SCHULING (“Executive”) and supersedes and replaces that certain Executive
Employment Agreement by and between the Company and Executive dated October 4, 2007. 
 RECITALS: 
 Executive is currently employed by the Company as its Senior Vice President and Chief Financial Officer. 
 The Company and Executive desire to formally state the terms and conditions of Executive’s employment by the Company and to provide Executive with
certain benefits upon a qualifying termination of such employment. 
 The Company desires to employ Executive in the executive capacity
hereinafter stated, and the Executive desires to enter into the employ of the Company in such capacity for the period and with the terms and conditions set forth herein. 
 AGREEMENT: 
 NOW, THEREFORE, in consideration of
the promises and the covenants set forth in this Agreement and for other valuable consideration, the parties hereby agree as follows: 
 1. Employment. The Company hereby employs Executive as Senior Vice President and Chief Financial Officer, assigned with responsibilities to do and perform all services, acts, or things necessary or advisable to manage and
conduct the business of the Company, subject at all times to the policies set by the Board of Directors of the Company (the “Board”), and to the consent of the Board when required by the terms of this contract. Executive hereby
accepts such employment and agrees to devote such time and energies as appropriate to fulfill all responsibilities to the Company. Executive shall be employed at will. 
 2. Compensation. In consideration for all services rendered by Executive under this Agreement, Executive shall receive the compensation described in this Section 2. All such compensation shall be
paid subject to appropriate tax withholding and similar deductions. 
 (a) Salary. Executive shall be paid an
initial annual salary of $285,000, payable in accordance with the Company’s normal practices in the payment of salary and wages practices, in equal installments, but not less than 26 increments annually. 
 (b) Executive Benefit and Incentive Compensation Plans. During employment hereunder, Executive shall be entitled to receive
those benefits which are routinely made available to executive officers of the Company, including participation in any executive stock ownership plan, profit sharing plan, incentive compensation or bonus plan, retirement plan, Company-provided

 
life insurance, or similar executive benefit plans maintained or sponsored by the Company. The Company shall not take any action that would substantially
diminish the aggregate value of Executive’s fringe benefits as they exist as of the Effective Date of this Agreement or as the same may be increased from time to time. 
 (c) Expense Reimbursement. The Company shall promptly reimburse Executive for all reasonable expenses necessarily incurred
during conduct of Company business, and for which adequate documentation is presented, but in no event later than December 31 of the year following the year in which the expense was incurred. 
 (d) Personal Time Off. Executive shall be entitled to paid time off in accordance with the Company’s policies
applicable to executives. 
 3. Termination. Executive’s employment may be terminated as follows, with the following
effects: 
 (a) Death. Executive’s employment shall terminate immediately upon the Executive’s death,
in which event the Company’s only obligations hereunder shall be to pay all compensation and expense reimbursements owing for services rendered and reasonable business expenses incurred by the Executive prior to the date of his death.

 (b) Disability. In the event the Executive is disabled from performing his assigned duties under this
agreement due to illness or injury for a period in excess of forty-five (45) consecutive days or a period or periods of more than one hundred and twenty (120) days in the aggregate in any twelve month period, the Board, in its sole
discretion, may terminate Executive’s employment immediately upon written notice to Executive, in which event the Company’s only obligations hereunder shall be to pay all compensation and expense reimbursements owing for services rendered
and reasonable business expenses incurred by the Executive prior to the effective date of termination. 
 (c) For
Cause. The Company may terminate Executive’s employment for Cause immediately upon written notice from the Board to Executive. For purposes of this Agreement, “Cause” means the occurrence of any one or more of the
following: (i) Executive’s conviction of or plea of nolo contendere to any felony crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) Executive’s attempted
commission of, or participation in, a fraud or act of dishonesty against the Company; (iii) Executive’s intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to
the Company; (iv) Executive’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) Executive’s gross misconduct. In the event Executive’s employment is terminated for Cause,
the Company shall have no further obligations to Executive other than to pay all compensation and expense reimbursements owing for services rendered and reasonable business expenses incurred by Executive prior to the effective date of such
termination. 

 (d) Without Cause. The Company in its sole discretion may terminate
Executive’s employment without Cause (as defined above) or prior warning immediately upon written notice from the Board to Executive, in which event, the Company shall pay to Executive all compensation and expense reimbursements owing for
services rendered and reasonable business expenses incurred by Executive prior to the effective date of termination, and provided such termination is a “separation from service” as such term is defined in Section 409A(a)(2)(A)(i) of
the Internal Revenue Code of 1986, as amended (the “Code”) and the applicable guidance thereunder, contingent upon Executive’s delivery to the Company of an effective Release and Waiver as provided in Section 3(e)
below, the Company shall also provide the following benefits to Executive: (i) severance consisting of continued payment of Executive’s base salary at the rate in effect as of the effective date of termination, less standard deductions and
withholdings, for a period of twelve (12) months following the effective date of termination, subject to acceleration of such payments into a single lump-sum cash severance payment in the event a Change in Control (as defined below, provided
that the Change in Control is an event described in Code Section 409A(a)(2)(A)(v)) of the Company has occurred prior to the date of termination (but not more than two years prior to such termination) or a Change in Control occurs within ninety
(90) days after the date of termination of Executive’s employment, provided that any such acceleration complies with the provisions of Code Section 409A(a)(3); (ii) upon timely election by Executive complying with COBRA, payment
of all premiums required to continue Executive’s medical, dental and vision insurance coverage pursuant to COBRA for a period of twelve (12) months following the date of termination; and (iii) immediately accelerate the vesting of all
options to purchase the common stock of the Company granted to Executive prior to the effective date of such termination (the “Options”) such that Executive shall be deemed vested as to the same number of shares as if
Executive had continued to be employed by the Company for a period of twelve (12) months following the effective date of such termination (subject to the additional accelerated vesting provided in Section 4(b) in the event Executive is
terminated by the Company without Cause within 90 days prior to or within 13 months following the effective date of a Change in Control). As a condition to receiving the continuing benefits specified in this Section 3(d), during the twelve
(12) month period following the Executive’s termination date, Executive shall not engage in any employment or business activity that is directly competitive with the Company’s business activities as of such termination date and
Executive shall not induce any employee of the Company to leave the employ of the Company. 
 (e) Release and
Waiver. As a condition to receiving the benefits specified in Sections 3(d) and 4(b) of this Agreement, Executive must deliver to the Company a fully effective waiver and release of claims in the form attached hereto as Exhibit A
(the “Release and Waiver”) within the time frame set forth therein, but in no event later than forty-five (45) days following the Executive’s termination date. 
 (f) Voluntary Termination by Executive. Executive may terminate his employment hereunder at any time, whether with or
without cause, effective sixty (60) days after delivery of written notice of such termination to the Company, except for Executive’s Emergency Need. “Emergency Need”, as used in this Section, is defined to be the
advent of illness or related health issues in Executive or his immediate family which a medical doctor would conclude poses a mortal health risk to that person. The Company shall have the option, in its sole discretion, to specify an earlier
termination date than that provided by Executive in the written notice. Upon voluntary termination pursuant to this Section, the Company shall have no further obligations to Executive other than to pay all compensation and expense reimbursements
owing for services rendered and reasonable business expenses incurred by Executive prior to effective date of termination as determined by the Company. 

 (g) Returning Company Documents. In the event of any termination of
Executive’s employment hereunder, Executive shall, prior to or on such termination deliver to the Company (and will not maintain possession of or deliver to anyone else) any and all devices, records, data, data bases software, software
documentation, laboratory notebooks, notes, reports, proposals, lists, customer lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, other documents or property, or reproductions of any of the above
aforementioned items belonging to the Company, its successors or assigns. 
 4. Change in Control. 
 (a) Option Acceleration Upon A Change in Control. Effective immediately upon the closing of a Change in Control of the
Company, the vesting of fifty percent (50%) of the then unvested shares of Common Stock subject to the Options shall be accelerated in full and shall be fully vested and immediately exercisable (and, if any Options have been early exercised by
Executive, the reacquisition or repurchase rights held by the Company with respect to the shares of Common Stock subject to such acceleration shall lapse in full, as appropriate). Thereafter, the balance of the Options’ unvested shares of
Common Stock subject to such Options shall vest in six (6) equal monthly installments over the six-month period immediately following the closing of the Change in Control, except as provided in Section 4(b) below. 
 (b) Benefits Upon Termination. In the event that Executive’s employment by the Company is terminated without Cause (as defined
above) or Executive terminates his employment for Good Reason (as defined below) within ninety (90) days prior to or within thirteen (13) months following the effective date of a Change in Control (as defined below) of the Company,
contingent upon Executive’s delivery to the Company of a fully effective Release and Waiver as provided in Section 3(e) and provided such termination is a “separation from service” as such term is defined in Code
Section 409A(a)(2)(A)(i), the Executive shall be entitled to the benefits and payments specified in Sections 3(d)(i) and 3(d)(ii) above, and the vesting of the unvested shares of Common Stock subject to the Options shall immediately accelerate
in full such that all of the shares of Common Stock subject to such Options shall be fully vested and immediately exercisable (and, if any Options have been early exercised by Executive, the reacquisition or repurchase rights held by the Company
with respect to the shares of Common Stock subject to such acceleration shall lapse in full, as appropriate). 
 (c) Change
in Control. “Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: 
 (i) any Exchange Act Person (as defined below) becomes the beneficial owner, directly or indirectly, of securities of the Company
representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control
shall not be deemed to occur (A) on account of the acquisition of securities of the Company by an investor, any 

 
affiliate thereof or any other Exchange Act Person from the Company in a transaction or series of related transactions the primary purpose of which is to
obtain financing for the Company through the issuance of equity securities or (B) solely because the level of beneficial ownership held by any Exchange Act Person (the “Subject Person”) exceeds the
designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur
(but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the beneficial owner of any additional voting securities that, assuming the
repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities beneficially owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur
(for purposes of this Section 4(c), “Exchange Act Person” means any natural person, entity or “group” (within the meaning of Section 13(d) or 14(d) of the Securities Exchange Act of 1934, as amended
(“Exchange Act”)), except that “Exchange Act Person” shall not include (A) the Company or any subsidiary of the Company, (B) any employee benefit plan of the Company or any subsidiary of the Company or any
trustee or other fiduciary holding securities under an employee benefit plan of the Company or any subsidiary of the Company, (C) an underwriter temporarily holding securities pursuant to an offering of such securities, (D) an entity
beneficially owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their beneficial ownership of stock of the Company; or (E) any natural person, entity or “group” (within the
meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the date of this Agreement, is the beneficial owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting
power of the Company’s then outstanding securities); 
 (ii) there is consummated a merger, consolidation or
similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not beneficially own,
directly or indirectly, either (A) outstanding voting securities representing more than fifty percent (50%) of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar transaction or
(B) more than fifty percent (50%) of the combined outstanding voting power of the parent of the surviving entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions relative to each
other as their beneficial ownership of the outstanding voting securities of the Company immediately prior to such transaction; 
 (iii) the stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur, except for a liquidation
into a parent corporation; 
 (iv) there is consummated a sale, lease, exclusive license or other disposition of all or
substantially all of the consolidated assets of the Company and its subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries to an entity, more
than fifty percent (50%) of the combined voting power of the voting securities of which are beneficially owned by stockholders of the Company in substantially the same proportions relative to each other as their beneficial ownership of the
outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or 

 (v) individuals who, on the date of this Agreement, are members of the Board (the
“Incumbent Board”) cease for any reason to constitute at least a majority of the members of the Board; (provided, however, that if the appointment or election (or nomination for election) of any new Board member was
approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of the Plan, be considered as a member of the Incumbent Board). 
 (d) Good Reason. “Good Reason” for the Executive to terminate the Executive’s employment hereunder shall mean
the occurrence of any of the following events without the Executive’s consent: 
 (i) a material adverse change in
the nature of the Executive’s authority, duties or responsibilities, as they exist on the Effective Date of this Agreement; 
 (ii) a material adverse change in the Executive’s reporting level requiring that the Executive report to a corporate officer or executive other than the Company’s Chief Executive Officer; 
 (iii) the relocation of the Company’s executive offices or principal business location to a point more than sixty
(60) miles from their location as of the Effective Date of this Agreement; or 
 (iv) a material reduction by the
Company of the Executive’s base salary as initially set forth herein or as the same may be increased from time to time. 
 Provided however
that, such termination by the Executive shall only be deemed for Good Reason pursuant to the foregoing definition if: (i) the Executive gives the Company written notice of the intent to terminate for Good Reason within thirty
(30) days following the first occurrence of the condition(s) that the Executive believes constitutes Good Reason, which notice shall describe such condition(s); (ii) the Company fails to remedy such condition(s) within thirty
(30) days following receipt of the written notice (the “Cure Period”); and (iii) the Executive terminates employment within thirty (30) days following the end of the Cure Period. 
 5. Application of Internal Revenue Code Section 409A. Benefits payable under the Agreement, to the extent of payments made from the
date of termination of the Executive through March 15th of the calendar year following such termination, are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations and thus payable
pursuant to the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations; to the extent such payments are made following said March 15th, they are subject to the distribution requirements of Code
Section 409A(a)(2)(A), including, without limitation, the requirement of Code Section 409A(a)(2)(B)(i) that payment to the Executive be delayed until 6 months after separation from service if the Executive is a “specified
Executive” within the meaning of the aforesaid section of the Code at the time of such separation from service. 

 6. Code Section 280G. If any payment or benefit Executive would receive pursuant to a
Corporate Transaction from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Code Section 280G, and (ii) but for this sentence,
be subject to the excise tax imposed by Code Section 4999 (the “Excise Tax”), then the Company shall cause to be determined, before any amounts of the Payment are paid to Executive, which of the
following two amounts would maximize Executive’s after-tax proceeds: (i) payment in full of the entire amount of the Payment (a “Full Payment”), or (ii) payment of only a part of the
Payment so that Executive receives the largest payment possible without the imposition of the Excise Tax (a “Reduced Payment”), whichever amount results in Executive’s receipt, on an after-tax basis,
of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. For purposes of determining whether to make a Full Payment or a Reduced Payment, the Company shall cause to be taken into
account all applicable federal, state and local income and employment taxes and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of
such state and local taxes). If a Reduced Payment is made, (i) the Payment shall be paid only to the extent permitted under the Reduced Payment alternative, and Executive shall have no rights to any additional payments and/or benefits
constituting the Payment, and (ii) reduction in payments and/or benefits shall occur in the following order: reduction of cash payments, cancellation of accelerated vesting of stock awards, and reduction of other benefits. In the event that
acceleration of compensation from Executive’s equity awards is to be reduced, such acceleration of vesting shall be canceled in the reverse order of the date of grant unless Executive elects in writing a different order for cancellation.

 The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective
date of the Corporate Transaction shall make all determinations required to be made under this Section 6. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual,
entity or group effecting the Corporate Transaction, the Company shall appoint a different nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with
respect to the determinations by such independent registered public accounting firm required to be made hereunder. The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations,
together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the date on which Executive’s right to a Payment is triggered (if requested at that time by the Company or Executive) or
at such other time as requested by the Company. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish
the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive
upon the Company and Executive. 

 7. Conflict Of Interest. During the Employment Period, Executive shall devote such time and
energies as appropriate to fulfill all responsibilities to the Company in the capacity set forth in Section 1. Executive shall be free to pursue business activities which do not interfere with the performance of his duties and responsibilities
under this Agreement, however, Executive shall not engage in any outside business activity which involves actual or potential competition with the business of the Company, except with the written consent of the Board. 
 8. Executive Benefit Plans. All of the Executive benefit plans referred to or contemplated by this Agreement shall be governed solely by the terms
of the underlying plan documents and applicable law. Nothing in this Agreement shall impair the Company’s right to amend, modify, replace, and terminate any and all such plans in its sole discretion as provided by law. This Agreement is for the
sole benefit of Executive and the Company, and is not intended to create an Executive benefit plan or to modify existing terms of existing plans. 
 9. Assignment. This Agreement may not be assigned by Executive. This Agreement shall bind and inure to the benefit of the Company’s successors and assigns, as well as Executive’s heirs, executors, administrators, and legal
representatives. The Company shall obtain from any successor, before the succession takes place, an agreement to assume the obligations and perform all of the terms and conditions of this Agreement. 
 10. Notices. All notices required by this Agreement may be delivered by first class mail at the following addresses: 
  

			
	 To Company:
	  	Genoptix, Inc.
		  	Attn: Board of Directors
		  	2110 Rutherford Road
		  	Carlsbad, CA 92008
		
	 To Executive:
	  	Douglas A. Schuling
		  	2110 Rutherford Road
		  	Carlsbad, CA 92008

 11. Amendment. This Agreement may be modified only by written agreement signed by both the
Company and Executive. 
 12. Choice Of Law. This Agreement shall be governed by the laws of the State of California, without regard
to choice of law principles. 
 13. Partial Invalidity. In the event any provision of this Agreement is void or unenforceable, the
remaining provisions shall continue in full force and effect. 
 14. Waiver. No waiver of any breach of this Agreement shall
constitute a waiver of any subsequent breach. 
 15. Complete Agreement. As of the Effective Date, this Agreement, together with the
stock option agreements and equity incentive plans governing the Options, constitutes the entire agreement between the parties in connection with the subject matter hereof and supersedes any and all prior or contemporaneous oral and written
agreements or understandings between the parties. 

 16. Headings. Headings in this Agreement are included herein for convenience of reference only and
shall not constitute a part of this Agreement for any other purpose. 
 17. Miscellaneous. Executive acknowledges full understanding
of the matters set forth herein and the obligations undertaken upon the execution hereof. 
 IN WITNESS
WHEREOF, the parties have executed this AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT as of the
date first written above. 
  

			
	GENOPTIX, INC.
		
	By:	 	/s/ Tina S. Nova, Ph.D.
	Name:	 	Tina S. Nova, Ph.D.
	Title:	 	President and Chief Executive Officer
		
	Dated:	 	November 25, 2008
	
	EXECUTIVE:
	
	/s/ Douglas A. Schuling
	DOUGLAS A. SCHULING
		
	Dated:	 	November 25, 2008

 EXHIBIT A 
 RELEASE AND WAIVER OF CLAIMS 
 In consideration of the payments and other
benefits set forth in the Amended and Restated Employment Agreement dated November 25, 2008 (the “Employment Agreement”), to which this form is attached, I, DOUGLAS A.
SCHULING, hereby furnish GENOPTIX, INC. (the “Company”), with the following release and waiver (“Release and Waiver”). 

In exchange for the consideration provided to me by the Employment Agreement that I am not otherwise entitled to receive, I hereby generally and
completely release the Company and its directors, officers, Executives, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, Affiliates, and assigns from any and all claims, liabilities and
obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Release and Waiver. This general release includes, but is not limited to: (1) all claims
arising out of or in any way related to my employment with the Company or the termination of that employment; (2) all claims related to my compensation or benefits from the Company, including, but not limited to, salary, bonuses, commissions,
vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good
faith and fair dealing; (4) all tort claims, including, but not limited to, claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local statutory claims, including,
but not limited to, claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age
Discrimination in Employment Act of 1967 (as amended) (“ADEA”), and the California Fair Employment and Housing Act (as amended). 
 I also acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or
suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits
under that section and any law of any jurisdiction of similar effect with respect to any claims I may have against the Company. 
 I
acknowledge that, among other rights, I am waiving and releasing any rights I may have under ADEA, that this Release and Waiver is knowing and voluntary, and that the consideration given for this Release and Waiver is in addition to anything of
value to which I was already entitled as an executive of the Company. I further acknowledge that I have been advised, as required by the Older Workers Benefit Protection Act, that: (a) the release and waiver granted herein does not relate to
claims under the ADEA which may arise after this Release and Waiver is executed; (b) I should consult with an attorney prior to executing this Release and Waiver; (c) I have twenty-one (21) days from the date of termination of my
employment with the Company in which to consider this Release and Waiver (although I may choose voluntarily to execute this Release and Waiver earlier); (d) I have seven (7) days following the 

 
execution of this Release and Waiver to revoke my consent to this Release and Waiver; and (e) this Release and Waiver shall not be effective until the
seven (7) day revocation period has expired unexercised and no benefits will be paid unless and until this Release and Waiver has become effective. In the event that this Release and Waiver is requested in connection with an exit incentive or
other employment termination program offered to a group or class of employees, I have forty-five (45) days to consider this Release and Waiver and I shall be provided with the information required by 29 U.S.C. Section 626 (f)(1)(H).

 This Release and Waiver constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with
regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated herein. This Release and Waiver may only be modified by a writing signed by both me and the a duly authorized member
of the Board of Directors of the Company. 
  

									
	Date:	 	____________________	 		 		 	 
		 		 		 		 	DOUGLAS A. SCHULINGAmended and Restated Medical Director Agreement

 Exhibit 10.28 
 AMENDED AND RESTATED MEDICAL DIRECTOR AGREEMENT 
 This Amended and Restated Medical Director
Agreement (“Agreement”) is effective as of 1st day of January, 2009, by and among Genoptix, Inc. (“Genoptix” or the “Laboratory”) and Pacific Medical Consultants, Inc., a California professional corporation
(“Corporation”) and Bashar Dabbas, M.D. (“Physician”). 
 RECITALS 
 A. Genoptix is a Delaware corporation that operates a licensed clinical laboratory located at 2110 Rutherford Road, Carlsbad, CA 92008 (the
“Laboratory”). Genoptix is in need of an experienced, qualified physician to serve as medical director of the Laboratory. 
 B.
Corporation employs Physician, who is an individual licensed to practice medicine in the State of California with at least two years’ experience directing or supervising the provision of laboratory tests of the same level of complexity as those
provided by the Laboratory. 
 C. Genoptix wishes to contract with Corporation to provide Physician to serve as medical director of the
Laboratory (“Medical Director”) to ensure that high standards of clinical laboratory services are performed in the Laboratory. 
 NOW, THEREFORE, in consideration of the above recitals, the terms and conditions hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and for their mutual reliance,
the parties hereto agree: 
 Section 1. Responsibilities of Corporation and Medical Director 
 During the term of this Agreement, Corporation shall perform and comply with, or, as applicable, cause Medical Director to perform and comply with, all
duties, responsibilities, conditions and covenants set forth in this Agreement, including but not limited to the following: 
 1.1
Medical Director/Administrative Services. Medical Director shall serve as Medical Director of the Laboratory and, in this role, shall provide to Genoptix those administrative services set forth in Exhibit A. 
 1.2 Absences. Corporation shall designate, subject to Genoptix’ approval, a qualified replacement, in the event of Medical
Director’s vacation or other temporary approved absence. The person who provides services on behalf of Corporation in Medical Director’s absence shall have at least two years experience directing or supervising the provision of laboratory
tests of the same level of complexity as those provided by the Laboratory and be bound by all terms of this Agreement. Genoptix shall have the right to approve the length of Medical Director’s absence, and any unapproved absence shall
constitute a breach of this Agreement. 

 1.3 Availability. At all times the Laboratory is open to provide laboratory services,
Medical Director, or Medical Director’s qualified replacement, shall be accessible to the Laboratory to provide, onsite, telephone or electronic consultation as needed. Medical Director shall inform Genoptix, on a monthly basis, of Medical
Director’s schedule and availability to provide services pursuant to this Agreement. 
 1.4 Time Commitment. Corporation
shall cause Medical Director to devote a minimum of twelve (12) hours per month providing the services described in this Agreement. 
 1.5 Limitation on Use of Space. No part of Genoptix’ premises, including the Laboratory, shall be used at any time as an office for the private practice of medicine or to analyze patient specimens other than Genoptix
patient specimens. 
 Section 2. Genoptix Responsibilities 
 2.1 Genoptix Services. 
 (a) Space and Equipment. Genoptix shall furnish
the premises for the Laboratory and such equipment as may be reasonably necessary for the proper operation and conduct of the Laboratory. Genoptix shall repair, replace or supplement such equipment and otherwise maintain it in good working order.

 2.2 General Services. Genoptix shall furnish ordinary janitorial services, maintenance services, and utilities, including
telephone service, as may be required for the proper operation and conduct of the space that it provides under this Agreement. 
 2.3
Supplies. Genoptix shall purchase, through its appropriate departments, all supplies as may be reasonably required for the proper operation of the Laboratory under this Agreement. 
 2.4 Genoptix Performance. The responsibilities of Genoptix shall be subject to Genoptix’ discretion and its usual purchasing
practices, budget limitations and applicable laws and regulations. 
 Section 3. Compensation 
 3.1 Compensation. On or before the fifteenth (15th) day of each calendar month during the term of this Agreement, beginning with the
second such month, and on or before the fifteenth (15th) day of the calendar month following the expiration or earlier termination of this Agreement, Genoptix shall pay Corporation Three Thousand Dollars ($3,000) per month for the provision of
laboratory-administrative services provided to Genoptix by Corporation under this Agreement during the preceding month. Corporation’s compensation for any partial calendar month during the terms of this Agreement shall be prorated based on the
actual days this Agreement is in effect during such partial calendar month. 
 Section 4. Term and Termination 
 4.1 Term. The term of this Agreement shall be for a period of three (3) years beginning on January 1, 2009 (the “Initial
Term”), unless terminated sooner pursuant to the terms and provision of this Agreement. Assuming that neither party is in default hereunder, this Agreement shall be automatically renewed upon the same terms and conditions set forth herein for
successive one (1) year terms (the “Renewal Term(s)”), unless terminated sooner pursuant to the provisions of this Agreement. The terms and conditions of this Agreement, including any amendments thereto, shall govern during the
Initial Term and each Renewal Term. 

 4.2 Termination. Notwithstanding the provisions of Section 4.1, this Agreement may be
terminated: 
 (a) By Genoptix at any time, without cause or penalty, upon sixty (60) days’ prior written notice to
the other party; 
 (b) Immediately by Genoptix in its sole discretion if Medical Director fails to maintain the professional
standards described in Section 5.1 of this Agreement; 
 (c) If (i) either party determines that any legislation,
regulation, rule or procedures are duly passed, adopted or implemented by a federal, state or local government or legislative body or any private agency; or (ii) either party or any of their affiliates, receives notice of any actual or
threatened decision, finding, or action by any governmental or private agency, court or third party (collectively referred to herein as an “Action”) which, if or when implemented, would have the effect of (1) revoking or jeopardizing
the status of the clinical laboratory license granted to Genoptix or any of Genoptix’ affiliates or (2) subjecting the parties or any of their respective affiliates, employees, officers, directors or agents to civil, criminal or
administrative prosecution, or other adverse proceeding on the basis of their participation herein; then the parties hereto shall attempt to amend this Agreement or alter its operation in order to avoid the Action. If, in the opinion of either
party, such amendment or alteration is not possible, this Agreement shall be terminated upon the written notice of either party; 
 (d) By either party in the event of a material breach, and in such event, the non-breaching party shall have the right to terminate this Agreement after providing thirty (30) days’ written notice to the breaching party, unless
such breach is cured to the satisfaction of the non-breaching party within the thirty (30) days; 
 (e) Immediately by
Genoptix upon the death of Medical Director; 
 (f) Immediately by Genoptix if Medical Director is determined by Genoptix, in
its sole and exclusive discretion, to be incompetent, or is permanently disabled so as to be unable to render services under the terms of this Agreement; 
 (g) Immediately by Genoptix if Medical Director ceases to be duly licensed to practice medicine under the laws of the State of California or ceases to be in good standing with the Medical Board of California; or

 (h) Immediately by Genoptix if any of Physician’s shares in Cartesian Medical Group, Inc. are transferred voluntarily,
involuntarily or by operation of law. 
 4.3 Rights Upon Termination. Upon any termination or expiration of this Agreement, all
rights and obligations of the parties shall cease except those rights and obligations which have accrued or expressly survive termination. 

 Section 5. Professional Standards 
 5.1 Licensure and Standards. Corporation shall at all times ensure that Medical Director: 
 (a) Is licensed to practice medicine in the State of California; 
 (b) Is certified by the
American Board of Pathology; 
 (c) Complies with all policies, rules and regulations of Genoptix; 
 (d) Maintains professional liability coverage in an amount and form acceptable to Genoptix; and 
 (e) Participates in continuing education as necessary to maintain licensure, certification and the current standard of practice.

 Section 6. Relationship Between the Parties 
 6.1 Independent Contractor. In the performance of this Agreement, it is mutually understood and agreed that Genoptix, Corporation, and Medical Director are at all times acting and performing as independent contractors, and as
such, they shall remain professionally and economically independent of each other. Genoptix and Corporation are not and no act, or failure to act by either party hereto, shall be construed to make or render the other party its partner, joint
venturer, employee or associate. Neither Corporation nor Corporation’s employees shall have a claim under this Agreement or otherwise against Genoptix for workers’ compensation, unemployment compensation, sick leave, vacation pay, pension
or retirement benefits, social security benefits, any other employee benefits, coverage of health, accident, disability or life insurance or payment of any federal, state or local taxes, including but not limited to FICA, FUTA and SDI, all of which
shall be the sole responsibility of Corporation. Corporation shall indemnify and hold harmless Genoptix from any and all loss or liability, if any, arising out of or with respect to any of the foregoing benefits or withholding requirements.

 6.2 Indemnification. Each party shall indemnify, defend and hold harmless the other party from any and all liability, loss,
claim, lawsuit, injury, cost, damage or expense whatsoever (including reasonable attorneys’ fees and court costs) arising out of, incident to or in any manner occasioned by the performance or nonperformance of any duty or responsibility under
this Agreement by such indemnifying party, or any of its employees, agents, contractors or subcontractors; provided, however, that neither party shall be liable to the other party hereunder for any claim covered by insurance, except to the extent
that the liability of such party exceeds the amount of such insurance coverage. 
 Section 7. General Provisions 
 7.1 Access to Records. To the extent required by Section 1861(v)(1)(1) of the Social Security Act, as amended, and by valid regulation
which is directly applicable to that Section, Corporation agrees to make available upon valid written request from the Secretary of HHS, the Comptroller General, or any other duly authorized representatives, this Agreement and the books, documents
and records of Corporation to the extent that such books, documents and records are necessary to certify the nature and extent of Genoptix’ costs for services provided by Corporation. 

 Corporation shall also make available such subcontract and the books, documents, and records of any
subcontractor if that subcontractor performs any of the Corporation or Medical Director’s duties under this Agreement at a cost of $10,000 or more over a twelve-month period, and if that subcontractor is organizationally related to Corporation.

 Such books, documents, and records shall be preserved and available for four (4) years after the furnishing of services by
Corporation pursuant to this Agreement. If Corporation is requested to disclose books, documents or records pursuant to this subsection for purposes of an audit, Corporation shall notify Genoptix of the nature and scope of such request and
Corporation shall make available, upon written request of Genoptix, all such books, documents or records. Corporation shall indemnify and hold harmless Genoptix in the event that any amount of reimbursement is denied or disallowed because of the
failure of Corporation or any subcontractor to comply with its obligations to maintain and make available books, documents, or records pursuant to this subsection. Such indemnity shall include, but not be limited to, the amount of reimbursement
denied, plus any interest, penalties and legal costs. 
 This section is intended to assure compliance with Section 1861 of the Social
Security Act, as amended, and regulations directly pertinent to that Act. The obligations of Corporation under this section are strictly limited to compliance with those provisions, and shall be given effect only to the extent necessary to insure
compliance with those provisions. In the event that the requirements of those provisions are reduced or eliminated, the obligations of the parties under this section shall likewise be reduced or eliminated. 
 7.2 Covenant Not to Compete. During the term of this Agreement, neither Corporation nor Medical Director shall consult, manage or provide
any services similar to those required to be performed under this Agreement for any other clinical laboratory within Los Angeles, Orange and San Diego Counties in California, without the prior written consent of Genoptix, which consent may be
withheld in Genoptix’ sole discretion. Corporation and Medical Director acknowledge that a breach of this Section 7.2 by either Corporation or Medical Director shall be deemed a material breach of this Agreement and will result in
irreparable injury to Genoptix, the precise amount of which is not readily ascertainable in monetary damages. Genoptix, in addition to any other remedies, shall be entitled to injunctive relief. 
 7.3 Nonsolicitation. During the term of this Agreement and for a twelve- (12) month period commencing on the date of the expiration or
earlier termination of this Agreement, neither Corporation nor Medical Director shall, without the prior written consent of Genoptix, employ or contract with, or solicit for employment or contract, any employee or independent contractor of Genoptix
to provide services similar to those provided in this Agreement. It is hereby agreed by all parties that in the event that Corporation or Medical Director employs or retains any employee or independent contractor of Genoptix, Corporation and/or
Medical Director shall pay to Genoptix, as liquidated damages and not as a penalty, a sum equal to one- (1) year’s salary of the person so employed or retained by Corporation and/or Medical Director. This sum represents the reasonable
endeavor by the parties hereto to estimate a fair compensation for the foreseeable and unforeseeable losses that might result from any such violation of this Section 7.3 by Corporation. 

 7.4 Confidential Information. Corporation and Medical Director recognize and understand
that, during the terms of this Agreement, Corporation and Medical Director shall receive, have access to or otherwise, become acquainted with various trade secrets, materials and other proprietary information related to Genoptix which is of a secret
or confidential nature (“Confidential Information”). During and after the term of this Agreement, Corporation and Medical Director shall not use the Confidential Information for any purposes other than the performance of this Agreement,
and shall not disclose such Confidential Information for any purposes other than the performance of this Agreement, and shall not disclose such Confidential Information received by Corporation or Medical Director to any third party, without prior
written consent of Genoptix. Upon the termination of this Agreement, Corporation and Medical Director shall promptly deliver to Genoptix all documents and material of any kind pertaining to Genoptix, and neither Corporation nor Medical Director will
take any documents, materials or copies thereof, whether on paper, magnetic or optical media or any other median, containing any Confidential Information. Corporation and Medical Director acknowledge that a breach of this Section 7.4 will
result in irreparable injury to Genoptix, the precise amount of which is not readily ascertainable in monetary damages. Genoptix, in addition to any other remedies, shall be entitled to injunctive relief. 
 7.5 Authorization for Agreement. The execution and performance of this Agreement by Corporation and Genoptix have been duly authorized by
all necessary corporate action, and is not in violation of: (a) any law, rule or regulation of any governmental entity having jurisdiction over either Genoptix or Corporation; or (b) the articles or bylaws of the parties hereto. This
Agreement constitutes the valid obligation of Genoptix and Corporation, enforceable in accordance with its terms. 
 7.6 Force
Majeure. Notwithstanding any provision contained herein to the contrary, Genoptix shall not be deemed to be in default hereunder for failing to perform any of the obligations to be performed by Genoptix pursuant to this Agreement if such failure
is the result of any labor dispute, act of God, inability to obtain labor or materials, governmental restrictions or any other cause without fault beyond the reasonable control of Genoptix. In addition, under no circumstances shall Genoptix be
liable for consequential damages or otherwise, for any failure or interruption of any utility or building service at the Laboratory. Genoptix shall not be liable for injury to Corporation’s business or medical practice or for any loss of income
or for damage to the goods, wares or other property of Corporation caused by any such failure or interruption under this Section 7.6. 
 7.7 No Third Party Beneficiary. None of the provisions herein contained are intended by the parties, nor shall they be deemed, to confer any benefit on any person not a party to this Agreement. 
 7.8 Governing Law. This Agreement shall be construed and governed by and under the laws of the State of California, as such laws are
applicable to agreements entered into and to be performed entirely within California between residents of California, without regard to conflict of law principles. 

 7.9 Entire Agreement; Amendments. Save for existing agreements between certain of the
parties with respect to confidentiality obligations, there are no other agreements or understandings, written or oral, between the parties, regarding this Agreement other than as set forth herein. This Agreement shall not be modified or amended
except by a written document executed by both parties to this Agreement and such written modification(s) shall be attached hereto. 
 7.10 Headings. The headings set forth herein are for the purpose of convenient reference only, and shall have no bearing whatsoever on the interpretation of this Agreement. 
 7.11 Notices. All notices which either party is required or may desire to give to the other under or in conjunction with this Agreement
shall be in writing, and shall be deemed to have been duly given upon receipt if: delivered in person or sent by facsimile to the party named below; or three (3) business days after it is deposited in the United States mail, if by certified or
registered mail, postage prepaid, return receipt requested; or the next business day if it is transmitted by Federal Express or similar overnight delivery service. All notices shall be addressed as follows: 
  

			
	If to Genoptix:	  	Genoptix, Inc.
		  	2110 Rutherford Road
		  	Carlsbad, CA 92008
		  	Attn.: Chief Financial Officer
		
	If to Corporation:	  	Pacific Medical Consultants, Inc.
		  	2110 Rutherford Road
		  	Carlsbad, CA 92008
		  	Attn: Bashar Dabbas, M.D.
		
	If to Medical Director:	  	Bashar Dabbas, M.D.
		  	2110 Rutherford Road
		  	Carlsbad, CA 92008

 or to such other address(es) or person(s) as may be designated by Genoptix or Corporation from time to time in
accordance with the provisions of this Section 7.11. 
 7.12 Nonwaiver. The waiver by either party of any breach of any
term, covenant or condition contained herein shall not be deemed to be a waiver of any subsequent breach of the same or any other term, covenant or condition contained herein. The subsequent acceptance of performance hereunder by a party shall not
be deemed to be a waiver of any preceding breach by the other party of any term, covenant or condition of this Agreement, other than the failure of such party to perform the particular duties so accepted, regardless of such party’s knowledge of
such preceding breach at the time of acceptance of such performance. 
 7.13 Counterparts. This Agreement may be executed in
counterparts, each of which shall be deemed to be an original, and all of such counterparts shall together constitute one and the same Agreement. 

 7.14 Severability. If any provision of this Agreement shall be determined to be invalid,
illegal, or unenforceable in any ,jurisdiction, the validity, legality, and enforceability of the remaining provisions, and of such provision in other jurisdictions, shall not be affected or impaired thereby. 
 7.15 Additional Documents. Each of the parties hereto agrees to execute any document or documents that may be requested from time to time by the
other party to implement or complete such party’s obligations pursuant to this Agreement and to otherwise cooperate fully with such other party in connection with the performance of such party’s obligations under this Agreement.

 7.16 Gender and Number. All references to the neuter gender shall include the feminine or masculine gender and vice versa, where
applicable, and all references to the singular shall include the plural and vice versa, where applicable. 
 IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be executed on the day and year first written above. 
  

					
	GENOPTIX, INC.	 		 	PACIFIC MEDICAL CONSULTANTS, INC.
			
	/s/ Tina S. Nova, Ph.D.	 		 	/s/ Bashar Dabbas, M.D.
	Tina S. Nova, Ph.D., President & CEO	 		 	Bashar Dabbas, M.D., President
			
	Date: October 31, 2008	 		 	Date: October 31, 2008
			
	BASHAR DABBAS, M.D.	 		 	
			
	/s/ Bashar Dabbas, M.D.	 		 	
			
	Date: October 31, 2008	 		 	

 EXHIBIT A 
 ADMINISTRATIVE SERVICES TO BE PROVIDED 
 Corporation shall cause Medical Director to:

 (a) Provide general administration of the day-to-day operations of the Laboratory; 
 (b) Implement Genoptix’ policies and procedures regarding the Laboratory; 
 (c) Ensure the accuracy and timely delivery of clinical laboratory testing results; 
 (d) Establish criteria for routine and abnormal clinical laboratory test result transfer; 
 (e) Assist in the evaluation and coordination of developmental initiatives for Laboratory’s clinical staff; 
 (f) Perform regular review of regional and national laboratories quality assurance data; 
 (g) Assist in the planning and arrangement of a cost effective annual budget for the Laboratory; 
 (h) Provide clinical diagnostic expertise for patients and physicians when full medical consultation is indicated; 
 (i) Be responsible for overall quality of the Laboratory; 
 (j) Fulfill all responsibilities required of laboratory directors supervising high complexity laboratories under the federal Clinical
Laboratories Improvement Act; and 
 (k) Provide advice and assistance in connection with such other administrative duties as
Genoptix may request from time to time.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}]]